vitronectin receptor inhibitors (Wyeth)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namevitronectin receptor inhibitors (Wyeth)
Drug Alias Namevitronectin receptor inhibitors (Wyeth-Ayerst)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin alpha-V/beta-3 antagonists
TargetsIntegrin alpha-V/beta-3
Therapy Area/IndicationsCoronary RestenosisBone DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesWyeth Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWyeth Research
Active IndicationsN/A
Inactive IndicationsCoronary RestenosisBone DiseasesNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A